San Diego-based mostly Viking Therapeutics marked alone as a serious competitor while in the weight loss drug marketplace in February soon after revealing promising data from the mid-stage trial of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs when specified being a weekly injection As well as in March